[MSI Status in Colorectal Cancer].
In recent years, immunotherapy has shown promising results in various types of cancers. Checkpoint inhibitor drugs developed for cancer immunotherapy have been approved by the US Food and Drug Administration(FDA)for adult patients with microsatellite instability-high(MSI-high)or mismatch repair deficient(dMMR)solid tumors. In addition, FDA approves nivolumabfor MSI-high or dMMR colorectal cancer. MSI status has an important role in colorectal cancer management.